Device Trial Radar · NCT04674969
Drug-Eluting Registry: Real-World Treatment of Lesions in the Peripheral Vasculature
Last checked: Nov 19, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
5,000
Planned (sponsor's estimate)
Start
Mar 29, 2021
Primary completion
Jan 2028
Study completion Jan 2028
Sponsor
- Lead sponsor
- Boston Scientific CorporationPublic (BSX)
- Sponsor type
- Industry
- First posted
- Dec 19, 2020
Design
- Study type
- Observational
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The ELEGANCE Registry's objective is to collect Real-World Data (RWD), including populations previously not represented in Peripheral Vascular Disease (PVD) trials, health economics data, and to support the safe use of commercially available Boston Scientific Corporation (BSC) drug-eluting devices for the treatment of lesions located in the peripheral vasculature.
Conditions
- Peripheral Vascular Diseases
Interventions
Any eligible commercially available Boston Scientific Corporation (BSC) drug-eluting device.Device
Ranger™ Paclitaxel-Coated Percutaneous Transluminal Angioplasty (PTA) Balloon Catheter; ELUVIA™ Drug-Eluting Vascular Stent System
Primary outcomes
What the sponsor says the trial is designed to measure.
- Major Adverse EventsTime frame: 12 months
- Lesion PatencyTime frame: 12 months
Locations
89 sites in 13 countries. Site status is shown where the registry gives one.
St. Bernard's Medical Center
Jonesboro, Arkansas · Recruiting
PIH Health Good Samaritan Hospital
Los Angeles, California · Recruiting
Cedars - Sinai Medical Center
Los Angeles, California · Recruiting
86 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.